Vaccination is the most effective method of preventing infectious diseases, and is considered one of the greatest achievements in medicine. Until today, various vaccines against several crucial diseases (including influenza, chicken pox, or HPV) have been developed that save millions of lives. Along the continuous emergence of new diseases and… Read More
Valneva has received a termination notice from the UK Government (HMG) in relation to the Supply Agreement for its Covid-19 vaccine candidate, VLA2001. The contract provides HMG with the right to terminate. HMG has alleged that the company is in breach of its obligations under the Supply Agreement, which… Read More
Amgen UK’s first-in-class medicine sotorasib (a targeted KRAS G12C inhibitor formerly named AMG 510) has become the first new cancer therapy to receive Conditional Marketing Authorisation for use1 across England, Scotland and Wales by the Medicines and Healthcare products Regulatory Agency (MHRA) under Project Orbis. This authorisation follows a review of sotorasib’s role in treating patients with… Read More
News round-up by DDW’s Megan Thomas for 6 – 10 September DDW’s Megan Thomas selects five stories which showcase results, data, partnerships and research which offer a promising future for both drug development and eventual treatment of a number of diseases. New potential therapy for… Read More
The "CRISPR Based Therapeutics Market by Type of Therapy, Therapeutic Approach, Therapeutic Area, and Key Geographical Regions: Industry Trends and Global Forecasts 2021-2030" report has been added to ResearchAndMarkets.com's offering. The report features a study of the current market landscape and future opportunity for the players involved in the development of CRISPR… Read More
Australian clinical-stage drug development company Noxopharm has released preliminary top-line data from its NOXCOVID Phase I clinical trial testing the suitability of idronoxil (Veyonda), a TBK1 (TANK-binding kinase 1) inhibitor, as an anti-inflammatory in patients with moderate Covid-19 disease. Veyonda currently has two main drug actions – a moderating… Read More
An in vitro study of drugs already approved by the US Food and Drug Administration (FDA) to treat a range of conditions has shown eight of them are also effective in slowing SARS-CoV-2 replication in infected human cells. The team led by University of Manchester scientists used the drugs… Read More
According to Thermo Fisher Scientific, lab managers, technology leaders and principal scientists in pharmaceutical, food and environmental laboratories can use its new mass specrometry (MS) portfolio and chromatography solutions to accelerate throughput and improve sensitivity to meet rapidly changing regulatory requirements and the fast responses needed to tackle emerging human and… Read More
IBM Research and Arctoris are investigating the application of AI and automation to accelerate closed loop molecule discovery. IBM Research has developed RXN for Chemistry, an online platform leveraging Natural Language Processing (NLP) architectures to automate synthetic chemistry. Representing chemical reactions via SMILES (Simplified Molecular Input Line Entry System),… Read More
Exscientia has entered a four-year collaboration with the Bill & Melinda Gates Foundation to develop small molecule therapeutics that tackle the current coronavirus pandemic and help prepare for future pandemics. The collaboration will initially focus on developing broad-spectrum coronavirus agents (e.g., SARS-CoV-2 and its variants, MERS), including accelerating Exscientia’s lead programme,… Read More
An upcoming influx of new therapies into the Pompe disease (PD) pipeline in the next decade is expected by GlobalData to provide a significant boost to the treatment market for this inherited, and often fatal, disorder that can greatly damage the heart and skeletal muscles. In fact, the market is expected to… Read More
South Korea is supporting innovative pharmaceutical companies by revising the health insurance benefits system. The new system of preferential drug pricing, if designed effectively, can boost innovation in the country’s pharmaceutical research, says GlobalData. According to GlobalData, the pharmaceutical market in South Korea is estimated to grow at a compound annual growth… Read More
Using an automated CE-SDS platform in efficient biosimilar comparability studies is a free-to-attend webinar which was hosted by DDW and supported by Bio-Techne on 29 September at 4PM BST. Watch on Demand here. The route to market for biosimilars places strong emphasis… Read More
Versantis’ lead product candidate VS-01 has been has granted orphan drug designation (ODD) by the Food and Drug Administration (FDA) for the treatment of hyperammonemia (HA) in inborn errors of metabolism (IEM). “This orphan drug designation from the FDA validates the scientific rationale of VS-01 in a… Read More
This is the latest episode of the free DDW podcast, “Putting virology back on the map: the fight against Covid-19”. It covers two articles written for Volume 22, Issue 1 – Winter 2020/21 of the Drug Discovery World Magazine. The first article is a case study titled… Read More
This podcast, Putting virology back on the map: the fight against Covid-19, covers two narrated articles written for Volume 22, Issue 1 – Winter 2020/21 of the Drug Discovery World Magazine. The first article is a case study titled “New technology in Covid research may accelerate… Read More
